In preclinical PDAC models, genetically or pharmacologically disrupting FN or FN-binding integrins can prevent CAFs from supporting pancreatic cancer cells at different steps of pancreatic cancer progression. This evidence concerns the gene FN1 and pancreatic neoplasm.